I was talking about the marketing of the older product, OxyContin. I would like to say regarding the newer formulation that it's remarkable, given the history—that is, the history of Purdue Pharma illegally making the claim in the United States that its product, OxyContin, which was the newer formulation at the time, had a lower abuse potential—that still today Purdue Pharma seems to be singing the same tune; i.e., saying that this even newer formulation that they have today has a lower abuse potential. I think that it's likely to result in exactly the same problem.
On February 13th, 2014. See this statement in context.